Page 73 - GPD-2-4

Gene & Protein in Disease Topical Me-EGF application in melanoma tumor growth

patterns of EGFR, HER2, HER3 and HER4 in non- paracrine signaling is required for melanoma cancer cell
melanoma skin cancer. Eur J Cancer, 37(2): 251–259. invasion. Cancer Res Commun, 2(5): 366–379.
https://doi.org/10.1016/s0959-8049(00)00364-6 https://doi.org/10.1158/2767-9764.CRC-22-0010
28. Liu S, Geng R, Lin E, et al., 2021, ERBB1/2/3 expression, 31. Wu HG, Song SY, Kim YS, et al., 2009, Therapeutic effect
prognosis, and immune infiltration in cutaneous melanoma. of recombinant human epidermal growth factor (RhEGF)
Front Genet, 12: 602160. on mucositis in patients undergoing radiotherapy, with or
https://doi.org/10.3389/fgene.2021.602160 without chemotherapy, for head and neck cancer: A double-
blind placebo-controlled prospective phase 2 multi-
29. Ma J, Han H, Liu D, et al., 2013, HER2 as a promising target institutional clinical trial. Cancer, 115(16): 3699–3708.
for cytotoxicity T cells in human melanoma therapy. PLoS
One, 8(8): e73261. https://doi.org/10.1002/cncr.24414
https://doi.org/10.1371/journal.pone.0073261 32. Wang GY, Xia ZF, Zhu SH, et al., 2003, Clinical observation
30. Pudelko K, Wieland A, Hennecke M, et al., 2022, Increased of the long-term effects of rhEGF on deep partial-thickness
microtubule growth triggered by microvesicle-mediated burn wounds. Zhonghua Shao Shang Za Zhi, 19(3): 167–168.

Volume 2 Issue 4 (2023) 9 https://doi.org/10.36922/gpd.1848